It is concluded that although Africans have low predisposition to thrombosis, they may well be pre-disposed to abnormal fibrin formation which could lead to various thromboembolic complications.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Fibrinogen, one of the most hemorheologically active plasma proteins, is associated with several cardiovascular risk factors, and the plasma concentration can alter dramatically during acute phase response and in a wide variety of clinical conditions.
📊
Key Findings & Data:Our results from patients with various disease conditions indicate that fibrinogen levels are in the pathological range and are significantly higher than in healthy controls (p<0.001).
💡
Conclusion & Impact:It is concluded that although Africans have low predisposition to thrombosis, they may well be pre-disposed to abnormal fibrin formation which could lead to various thromboembolic complications.
Fibrinogen, one of the most hemorheologically active plasma proteins, is associated with several cardiovascular risk factors, and the plasma concentration can alter dramatically during acute phase response and in a wide variety of clinical conditions. We have assessed fibrinogen levels in some known cardiovascular disorders, during usage of contraceptive pills, acute phase conditions and pregnancy. Our results from patients with various disease conditions indicate that fibrinogen levels are in the pathological range and are significantly higher than in healthy controls (p<0.001). It is concluded that although Africans have low predisposition to thrombosis, they may well be pre-disposed to abnormal fibrin formation which could lead to various thromboembolic complications.
AJAYI, O. I., FAMODU, A. A., OVİASU, E. (2007). Fibrinogen concentration: A marker of cardiovascular disorders in Nigerians. Turkish Journal of Hematology, Cilt: 24 - Sayı: 1, 18–22. https://ajindex.com/articles/413216
Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-15
Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6
Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994;71:593–5
Giansante C, Fiotti N, Cattin L, Da Col PG, Calabrese S. Fibrinogen, D-dimer and thrombin–antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost 1994;71:581-6
Stone MC, Thorp JM. Plasma fibrinogen--a major coronary risk factor. JR Coll Gen Pract 1985;35:565-9
Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7
Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscle Thromb 1994;14:54-9
Rosenson RS, Tangney CC, Itafner JM. Intra-individual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb 1994;14:1928-32
Reid HL, Obi CO, Oli JM. Reduced erythrocyte deformability and hyperfibrinogenemia in Nigerian diabetics with hemoglobin genotype HbAA. Acta Diabet Lat 1984;21:105-14
Famodu AA, Ojogwu LI, Okpere BE, Idaewor M, Jaiyesimi AEA. Plasma fibrinogen and fibrinolytic activity in Nigerian diabetics treated with insulin. Nig Med J 1995;29:53-5
Reid HL, Anah CO. Haemorheological parameters in hypertensive Nigerians with and without sickle cell trait. Angiology 1985;36:379-86